Association between SOST and/or anti-SOST antibodies with the clinical characteristics of patient cohorts with IBD and SpA/IBD.
| Variables | Ax-SpA/IBD, n = 45 | Per-SpA/IBD, n = 40 | SpA/IBD, n = 85 | IBD, n = 40 | ||||
|---|---|---|---|---|---|---|---|---|
| r | 95% CI | r | 95% CI | r | 95% CI | r | 95% CI | |
| SOST and anti-SOST | −0.34 | −0.57 to 0.05 | 0.07 | −0.41 to 0.50 | −0.62 | −0.76 to −0.40 | 0.09 | −0.46 to 0.40 |
| SOST and arthritis duration | 0.10 | −0.31 to 0.48 | 0.22 | −0.16 to 0.59 | −0.42 | −0.63 to −0.16 | NA | NA |
| anti-SOST and arthritis duration | 0.31 | −0.04 to 0.63 | 0.22 | −0.18 to 0.59 | 0.48 | 0.25 to 0.68 | NA | NA |
Statistical analysis was performed using r Spearman correlation and 95% CI. Values in bold face are statistically significant. SOST: sclerostin serum levels; anti-SOST: anti-SOST immunoglobulin G serum levels; SpA/IBD: inflammatory bowel disease–associated spondyloarthritis, with axial (ax-) or peripheral (per-) articular involvement using radiographic or magnetic resonance imaging; IBD: inflammatory bowel disease patients without articular disease; NA: not applicable.